JPH08505282A - Ｂ群連鎖球菌に対する複合ワクチン - Google Patents

Ｂ群連鎖球菌に対する複合ワクチン

Info

Publication number
JPH08505282A
JPH08505282A JP6511389A JP51138993A JPH08505282A JP H08505282 A JPH08505282 A JP H08505282A JP 6511389 A JP6511389 A JP 6511389A JP 51138993 A JP51138993 A JP 51138993A JP H08505282 A JPH08505282 A JP H08505282A
Authority
JP
Japan
Prior art keywords
group
protein
streptococcus
sequence
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP6511389A
Other languages
English (en)
Japanese (ja)
Inventor
エル． マイケル，ジェイムズ
エル． キャスパー，デニス
エム． オースーベル，フレデリック
シー． マドフ，ローレンス
Original Assignee
ザ、ゼネラル、ホスピタル、コーポレーション
ブリカム、エンド、ウィミンズ、ホスピタル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ、ゼネラル、ホスピタル、コーポレーション, ブリカム、エンド、ウィミンズ、ホスピタル filed Critical ザ、ゼネラル、ホスピタル、コーポレーション
Publication of JPH08505282A publication Critical patent/JPH08505282A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP6511389A 1992-11-02 1993-11-02 Ｂ群連鎖球菌に対する複合ワクチン Pending JPH08505282A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96886692A 1992-11-02 1992-11-02
US07/968,866 1992-11-02
PCT/US1993/010506 WO1994010317A2 (en) 1992-11-02 1993-11-02 Conjugate vaccine against group b streptococcus

Publications (1)

Publication Number Publication Date
JPH08505282A true JPH08505282A (ja) 1996-06-11

Family

ID=25514876

Family Applications (1)

Application Number Title Priority Date Filing Date
JP6511389A Pending JPH08505282A (ja) 1992-11-02 1993-11-02 Ｂ群連鎖球菌に対する複合ワクチン

Country Status (14)

Country Link
EP (1) EP0669985A1 (xx)
JP (1) JPH08505282A (xx)
KR (1) KR100349331B1 (xx)
AU (1) AU689452B2 (xx)
CA (1) CA2146926A1 (xx)
FI (1) FI951979A (xx)
HU (1) HU220198B (xx)
IL (1) IL107458A0 (xx)
NO (1) NO951629L (xx)
NZ (1) NZ258684A (xx)
PL (1) PL177302B1 (xx)
RU (1) RU2209247C2 (xx)
WO (1) WO1994010317A2 (xx)
ZA (1) ZA938171B (xx)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6015889A (en) * 1993-03-19 2000-01-18 Gunnar Lindahl Protein rib, a cell surface protein that confers immunity to many strains of the group B streptococcus: process for purification of the protein, reagent kit and pharmaceutical composition
US6284884B1 (en) 1995-06-07 2001-09-04 North American Vaccine, Inc. Antigenic group B streptococcus type II and type III polysaccharide fragments having a 2,5-anhydro-D-mannose terminal structure and conjugate vaccine thereof
US6426074B1 (en) * 1997-03-19 2002-07-30 The Brigham And Women's Hospital Inc. Group B Streptococcus vaccine
US7098182B2 (en) 1998-07-27 2006-08-29 Microbial Technics Limited Nucleic acids and proteins from group B streptococcus
JP2002531054A (ja) * 1998-07-27 2002-09-24 マイクロビアル テクニクス リミティッド Ｂ群連鎖球菌由来の核酸およびタンパク質
HUP0201022A3 (en) * 1998-12-22 2004-07-28 Microscience Ltd Wokingham Outer surface proteins, their genes, and their use
US6890539B2 (en) 1998-12-22 2005-05-10 Microscience, Ltd. Genes and proteins, and their use
GB9910375D0 (en) * 1999-05-05 1999-06-30 Lindahl Gunnar Vaccine composition
WO2002031156A2 (en) * 2000-10-13 2002-04-18 Shire Biochem Inc. Bvh-a2 and bvh-a3 antigens of group b streptococcus
CN1787839B (zh) 2003-03-07 2011-09-28 惠氏控股公司 用于抗医院内感染的免疫的多糖-葡萄球菌表面粘附素载体蛋白缀合物
ES2586418T3 (es) 2007-04-16 2016-10-14 Minervax Aps Vacuna de proteína de fusión
JP5788796B2 (ja) 2008-08-28 2015-10-07 ノバルティス アーゲー 終止コドンのリードスルーによるポリペプチドアイソフォームの細胞表面提示
CA3001433A1 (en) 2015-10-21 2017-04-27 Minervax Aps Immunogenic fusion protein
US10888610B2 (en) 2015-12-30 2021-01-12 Minerv Ax Aps Immunogenic complex for eliciting protective immunity against group b streptococcus
US20200254083A1 (en) 2017-06-16 2020-08-13 Glaxosmithkline Biologicals Sa Method of treatment
CN114728051A (zh) 2019-11-22 2022-07-08 葛兰素史克生物有限公司 细菌糖糖缀合物疫苗的剂量和施用
EP4066854A1 (en) 2021-03-29 2022-10-05 MinervaX Immunogenic fusion protein

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0302887B1 (en) * 1986-04-16 1994-06-22 The Brigham And Women's Hospital, Inc. Bacterial antigens, antibodies, vaccines, and methods of manufacture
IL95578A (en) * 1989-09-15 1998-08-16 Gen Hospital Corp A vaccine made from polysaccharide and protein

Also Published As

Publication number Publication date
KR100349331B1 (ko) 2003-01-06
FI951979A (fi) 1995-06-29
HU220198B (hu) 2001-11-28
EP0669985A1 (en) 1995-09-06
WO1994010317A2 (en) 1994-05-11
AU5665494A (en) 1994-05-24
KR950704492A (ko) 1995-11-20
FI951979A0 (fi) 1995-04-26
NO951629L (no) 1995-07-03
NO951629D0 (no) 1995-04-28
PL177302B1 (pl) 1999-10-29
WO1994010317A3 (en) 1994-07-07
RU2209247C2 (ru) 2003-07-27
IL107458A0 (en) 1994-02-27
ZA938171B (en) 1995-03-07
CA2146926A1 (en) 1994-05-11
HUT70981A (en) 1995-11-28
PL308555A1 (en) 1995-08-21
NZ258684A (en) 1997-04-24
AU689452B2 (en) 1998-04-02

Similar Documents

Publication Publication Date Title
US6342223B1 (en) Immunogenic composition for group B Streptococcus
US6426074B1 (en) Group B Streptococcus vaccine
JPH08505282A (ja) Ｂ群連鎖球菌に対する複合ワクチン
JPH11513371A (ja) 肺炎球菌遺伝子、その一部、それ由来の発現産物、ならびに該遺伝子、該遺伝子の一部分、および該遺伝子産物の使用
JPH09224680A (ja) 肺炎球菌タンパクの構造遺伝子
JP3447713B2 (ja) Ｂ群連鎖球菌に対する複合ワクチンを製造するための防御的タンパク質抗原をコードする遺伝子配列からなる組換え分子
WO2004020609A9 (en) Streptococcus pneumoniae antigens for diagnosis, treatment and prevention of active infection
US7049419B2 (en) Pneumococcal surface protein C (PspC), epitopic regions and strain selection thereof, and uses therefor
AU722078B2 (en) Conjugate vaccine against group B Streptococcus
Lebogo Pre-clinical evaluation of pneumococcal vaccine candidate molecules in a mouse pneumococcal pneumonia model
WO2019157188A2 (en) Compositions and methods for cross-protection against pneumococcal disease